UC Davis Health
UC Davis MIND Institute

Publications | Translational Psychophysiology and Assessment Laboratory | UC Davis MIND Institute

T-PAL Publications

Translational Psychophysiology and Assessment Laboratory (T-PAL)

    1. Berry-Kravis EM, Lindemann L, Jnch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman RJ, Spooren W, & Jacquemont S (2018). Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome. Nature Reviews Drug Discovery 17, 280-299.
    2. Shickman R, Famula J, Tassone F, Leehey M, Ferrer E, Rivera SM & Hessl D (2018). Age- and CGG Repeat Length-Related Slowing of Manual Movement in FMR1 carriers: A Prodrome of FXTAS? Movement Disorders 33(4), 628-636.
    3. Ligsay A, Van Dijck A, Nguyen DV, Lozano R, Chen Y, Bickel ES, Hessl D, Schneider A, Angkustsiri K, Tassone F, Ceulemans B, Koy RF, & Hagerman RJ (2017). A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. Journal of Neurodevelopmental Disorders 9(1), 26.
    4. Wang JY, Hessl D, Hagerman RJ, Simon TJ, Tassone F, Ferrer E, Rivera SM (2016). Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation. Neurobiology of Aging (55), 11-19. PMID: 28391068.
    5. Hessl D, Sansone S, Berry-Kravis E, Riley K, Widaman K, Abbeduto L, Schneider A, Coleman J, Oaklander D, Rhodes K, & Gershon R (2016). The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions. Journal of Neurodevelopmental Disorders 8(1), 35.
    6. Gossett A, Sansone S, Schneider A, Johnston C, Hagerman RJ, Tassone F, Rivera SM, Seritan A, & Hessl D (2016). Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome.  American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 171(8), 1139-1147.
    7. Hessl D & Grigsby (2016). Fragile X-associated tremor/ataxia syndrome: Another phenotype of the FMR1 Special Issue, Frontiers in Clinical Neuropsychology: Fragile X-Associated Tremor-Ataxia Syndrome. The Clinical Neuropsychologist 30(6), 810-814.
    8. Schneider A, Johnston C, Tassone F, Sansone S, Hagerman RJ, Ferrer E, Rivera SM, & Hessl D (2016). Broad autism spectrum and obsessive-compulsive symptoms in adults with the fragile X premutation. Special Issue, Frontiers in Clinical Neuropsychology: Fragile X-Associated Tremor-Ataxia Syndrome. The Clinical Neuropsychologist 30(6), 929-943.
    9. Wang JY, Ngo MM, Hessl D, Hagerman RJ, & Rivera SM (2016). Robust machine learning-based correction on automatic segmentation of the cerebellum and brainstem.  PLoS ONE 11(5): e0156123.
    10. Cordeiro L, Abucayan F, Hagerman RJ, Tassone F, & Hessl D (2015). Anxiety disorders in premutation carriers: Preliminary characterization of probands and non-probands.  Intractable and Rare Diseases Research 4(3), 123-130.
    11. Au J, Berkowitz-Sutherland L, Schneider A, Schweitzer JB, Hessl D, & Hagerman RJ (2014). A feasibility trial of Cogmed working memory training in fragile X syndrome. Journal of Pediatric Genetics 3(3).
    12. Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, & Hessl D (2014).  Improving IQ measurement in intellectual disabilities using true deviation from population norms.  Journal of Neurodevelopmental Disorders 6(16), 1-14.
    13. McCormick C, Hessl D, Macari SL, Ozonoff S, Green C, Rogers SJ (2014). Electrodermal and behavioral responses of children with autism spectrum disorders to sensory and repetitive stimuli.  Autism Research 7(4), 468-480.
    14. Ballinger EC, Cordeiro L, Chavez AD, Hagerman RJ, & Hessl D (2014).  Emotion potentiated startle in fragile X syndrome.  Journal of Autism and Developmental Disabilities 44(10), 2536-2546.
    15. Cohen S, Masyn K, Mastergeorge A, & Hessl D (2013).  Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome. Journal of Clinical Child and Adolescent Psychology. PMID: 24156344.
    16. Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman RJ, & Hessl D (2013). Electrocortical changes associated with minocycline treatment in fragile X syndrome.  Journal of Psychopharmacology, 27(10), 965-963. PMID: 23981511.
    17. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Michener A, & Urv TK (2013). Outcome measures for clinical trials in fragile X syndrome. Journal of Developmental and Behavioral Pediatrics, 34(7) 508-522.  PMID: 24042082.
    18. Russo-Ponsaran N, Yesensky J, Hessl D, & Berry-Kravis E (In press).  Feasibility, reproducibility, and clinical validity of the Pediatric Anxiety Rating Scale – Revised for fragile X syndrome.  American Journal on Intellectual and Developmental Disabilities 119(1), 1-16.
    19. Schneider A, Seritan A, Tassone F, Rivera S, Hagerman RJ, & Hessl D (2013).  Psychiatric features in high-functioning adult brothers with fragile X spectrum disorders.  The Primary Care Companion for CNS Disorders, 15(2).
    20. Leigh MJS, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, & Hagerman RJ (2013). A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. Journal of Developmental and Behavioral Pediatrics, 34(3), 147-155. PMID: 23572165
    21. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DM, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, & Hagerman RJ (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, Phase 2 trial. Science Translational Medicine, 4(152): 152ra127. PMID: 22993294
    22. Knox A, Schneider A, Abucayan F, Hervey C, Tran C, Hessl D & Berry-Kravis E (2012).  Feasibility, Reliability, and Clinical Validity of the Tests of Attentional Performance for Children (KiTAP) in Fragile X Syndrome (FXS).  Journal of Neurodevelopmental Disorders 4: 2. PMID: 22958782)
    23. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, & Hessl D (2011).  Psychometric study of the Aberrant Behavior Checklist in fragile X syndrome and implications for targeted treatment.  Journal of Autism and Developmental Disorders 42(7), 1377-1392. PMID: 21972117
    24. Hessl D, Wang JM, Schneider A, Koldewyn K, Le L, Iwahashi C, Tassone F, Hagerman PJ, & Rivera SM (2011).  Deficient FMRP underlies amygdala dysfunction in carriers of the fragile X premutation.  Biological Psychiatry, 70(9), 859-865. PMID: 21783174
    25. Farzin F, Scaggs F, Hervey C, Berry-Kravis E, & Hessl D (2011).  Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome.  Journal of Autism and Developmental Disorders, 41(11), 1515-1522. PMID: 21267642
    26. Cordeiro, L., Ballinger, E., Hagerman RJ, & Hessl D (2011). Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: Prevalence and characterization.  Journal of Neurodevelopmental Disorders 3, 57-67. PMID: 21475730
    27. Schneider, A., Ballinger, E., Chavez, A., Tassone F, Hagerman RJ, & Hessl D (2010).  Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome.  Neurobiology of Aging, 33(6), 1045-1053.  PMID: 20961665
    28. Yuhas J, Cordeiro L, Tassone F, Ballinger L, Schneider A, Long JM, Ornitz EM, & Hessl D (2010).  Sensorimotor gating in idiopathic autism and autism associated with fragile X syndrome. Journal of Autism and Developmental Disorders, 41(2), 248-253.  PMID: 20521090
    29. Farzin F, Rivera SM, & Hessl D (2009).  Face processing in individuals with fragile X syndrome: An eye tracking study.  Journal of Autism and Developmental Disorders, 39(6) 946-952.
    30. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchinson J, Snape M, Tranfaglia M, Nguyen DV, & Hagerman RJ (2009).  A pilot open-label singe-dose trial of Fenobam in adults with fragile X syndrome.  Journal of Medical Genetics, 46(4) 266-271. PMID: 19126569
    31. Hessl D, Nguyen DV, Green C, Chavez A, Tassone F, Hagerman RJ, Senturk D, Schneider A, Lightbody A, Reiss AL & Hall S (2009). A solution to limitations of cognitive testing in children with intellectual disabilities: The case of fragile X syndrome.  Journal of Neurodevelopmental Disorders, 1, 33-45. PMID: 19865612
    32. Hessl D, Cordeiro L, Yuhas J, Campbell A, Ornitz E, Berry-Kravis E, Chruscinski E, Hervey C, Long JM, & Hagerman RJ (2009).  Prepulse inhibition in fragile X syndrome: Feasibility, reliability and implications for treatment.  American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 150B(4) 545-553
    33. Hessl D, Tassone F, Cordeiro L, Koldewyn K, McCormick C, Green C, Wegelin J, Yuhas J, & Hagerman RJ (2008).  Aggression and stereotypic behavior in males with fragile X syndrome: Moderating secondary genes in a “single gene” disorder.  Journal of Autism and Developmental Disorders 38(1), 184-189.
    34. Hessl D, Rivera SR, Koldewyn K, Cordeiro L, Adams J, Tassone F, Hagerman PJ, & Hagerman RJ (2007).  Amygdala dysfunction in men with the fragile X premutation.  Brain 130(2), 404-416.
    35. Hessl D, Tassone F, Loesch, DZ, Berry-Kravis E, Leehey M, Gane LW, Barbato I, Rice C, Gould E, Hall DA, Grigsby J, Wegelin JA, Harris S, Lewin F, Weinberg D, Hagerman PJ & Hagerman RJ (2005).  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.  American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 139B: 115-121.